financial today's welcome everyone warm the who Thank highlights you, a dialed year. Özlem, key I'll for to my XXXX and with start in call. section
into During able the performance. were underline maintain diving like again would of key we the for some past a to strong XXXX to financial year, figures the by I financial year. this
whereby of Based and and cash reported profit year €XX.XX. €XX.X XXXX. vaccines Our fully for reached earnings updated the diluted per on flow financial generated ended XXXX XX, the guidance an revenues, share we billion comprised operating from COVID-XX year our end the of revenues €XX.X €XX.X mainly December total November our met billion billion a of strong during XXXX, generated we upper on basis
cash position, the third €XX.X Pfizer, With cash quarter year our profit respect with to Company's financial received financial XXXX. from the and year, we ended the of share cash billion collaboration in gross end settling the our of XXXX Subsequent €X.X have to partner, equivalents. of billion the for we
in the Let's actuals the comparison call XXXX. November updated year recently continue earnings next the that of the presents our XXXX with between slide financial our last to guidance in
guidance €XX billion. of As of our just recognized the reaching revenues billion vaccine €XX billion end we upper COVID-XX mentioned, in €XX.X to
come invoiced to of In vaccine following the in in detail revenues allocation billion doses I'll the in the we approximately one XXXX. back X of more slides. COVID-XX total,
we During to so year, €X,XXX XXXX year Omicron The the bivalent of of contributed for the our the spend. our expenses COVID-XX our reached of financial guidance the million, R&D resulting production ended upper from vaccines expenses prelaunch R&D adapted end March around our that XXXX.
existing candidates with our pipeline line oncology accelerating and infectious in diseases and in broadening on focused activities expectations. R&D core Our of product our
expenses. SG&A to Moving
by were internal and guidance rapid growth, we activities. met expenses During including March mainly XXXX XXXX. accelerating for our year, our €XXX our the operating SG&A million financial recognized of expenses, supporting driven The hence,
included spending delays below to remained mainly certain expectation, and infrastructure to amounted construction year finishing various production financial XXXX due and The €XXX capital investments our our capacities. in projects. Our in million expenditures
Certain financial During associated year, on not have the tax under though, from an share-based an tax XX%, the meeting cash our Considering the guidance. rate XXXX current XX%. recognized have effect, savings in did expenses our cost-effective this tax those directly. impact effective income we income about is payment annual equity tax of rate IFRS. Hence, effective rate been reached annual with savings effective the amended programs
Let's benefiting saw now revenues to year, U.S. of end corresponds from Compared collaboration COVID-XX our some dollar we by billion next switch year of XXXX to a upper demand vaccine and decrease the The stronger-than-expected partners COVID-XX financial €XX.X guidance, favorable reached vaccines. the COVID-XX page. the revenues which the development. with our previous of sales in our vaccine
on Let revenue give our some you details more me stream.
have rights. been between and COVID-XX and on vaccine us, marketing Pfizer As territories collaborations, Fosun our distribution based a Pharma allocated on reminder,
COVID-XX related the of net from on generate €XX.X in Our meaning sales XXX% that profit represent billion we COVID-XX These a revenues. included vaccine figure, collaboration territories. to vaccine a margin those our revenues gross share partner revenues gross
we to between statements the our financial in profit based As have SEC, mentioned in partner some and and us. collaboration shared explained on detail estimated our on and more filings past our with data preliminary Pfizer the is, share extent,
COVID-XX vaccine territory COVID-XX financial customers COVID-XX shipments the revenues collaboration towards our partners during billion bivalent vaccine end for were to revenues year. Also vaccine by Omicron in from were adapted territory driven the COVID-XX reached €X.X direct significantly cells XXXX included our the our from year. vaccine sales financial to XXXX. in in revenues XXXX of billion our €X.X of the sales Our Revenues of
to for The manufacturing redundant. with variances manufacturing due to quarter expenses the organizations production XXXX. and derived the year and influenced became that contract capacity sales inventories moving as under financial write-offs full results of are related fourth to collaboration from to our such the from be Pfizer by time time costs I'll of
amounted the caused mainly drop me period. to prior the QX. let XXXX move fourth to compared year This of billion €X.X slide, revenues was release for comparative Having on in by sales previous cost the that in of provisions quarter €X.X explained billion our to the of
For prior for period. €X year, comparative amounted of compared the billion XXXX financial year sales billion €X.X the to cost the to
sales sales cost sales comprised the cost our Pfizer share gross sales. of of COVID-XX our based collaboration partner we included of vaccine owe profit The that from our on
effects of capacities new internal formulation, our from impacted bivalent sales adapted redundant. the by and the XXXX. was contract of and of vaccine that by capacities, the cost during the expenses addition, XX, switch inventory from manufacturing year-end COVID-XX In driven with Omicron to derived to from arising The production manufacturing a the organizations COVID-XX vaccine became contracts vaccine write-offs for due monovalent introduction accelerating expenses were December
€X.X and compared to of Research the development period comparative in billion expenses fourth reached XXXX XXXX. the billion for for quarter €X.X
the driven to financial to compared production €X.X XXXX bivalent under COVID-XX due pipeline benefits candidates. in the vaccine an for by increase year share-based For our period. and comparative from as with connection expenses as the year, and as incurred well adapted studies expenses our approximately arrangements. €X.X amounted the The and development Omicron increase our of security billion, increase increase research payment further development expenses resulting from billion progressing was for in headcount was wages, before, stated mainly and to prior social an expenses clinical The in
General period XXXX. expenses of fourth as XXXX and the billion amounted in comparative €X.X to for as for quarter both the administrative well
compared and €X.X resulting prior the to administrative services purchased For increase an XXXX wages, to year expenses increased IT an consulting the as year, headcount. billion increase security social as was financial The IT due in for mainly mainly billion and €X.X increased G&A and for expenses comparative external in from increase expenses, in the period. expenses for services, well general were benefits
in general to business Our the and increase also transactions contributed expense. administrative development
billion compared of XXXX period Income the with for amount billion fourth an comparative taxes to accrued in €X.X XXXX. of were €X.X quarter the for
to in XXXX an billion financial reached with year prior is billion our effective amount period. XXXX compared income was of year and financial the For the for taxes approximately comparative the rate The expectations. derived tax income year, €X.X €X.X for XX% line
billion €X.X compared comparative period the net quarter for For to €X.X billion reached in of the fourth XXXX. XXXX, profit
reached For year ended the for net the billion million to €X.X comparative profit compared XXXX, year period. €XX.X XX prior
for quarter XXXX the fourth per earnings compared comparative in to of for the €X.XX amounted period share diluted to Our XXXX. €XX.XX
financial to €XX.XX our share XXXX earnings year, diluted to XXXX. the amounted For per €XX.XX in compared
from move our financial now at look have following return Let's should our year. our during to to XXXX shareholders the the a benefit shareholders that We believe strong the slide performance. and
Meeting payment our ordinary which €X Following per the June out share of XXXX, cash an in to was of Annual aggregate billion. General led special paid to a shareholders, approximately €X.X dividend
allowing a In ADSs addition, $X.X we March repurchase in XXXX. in share XXXX to amount billion the ADSs, XXXX, of us during and authorized year to the repurchase up of program
our December a November on with repurchase tranche XXXX, XXXX. On And repurchase $X second billion value XXXX. this share program to commenced. up of of $X.X started with May a of share our of we program X, value which ended XX, authorized In X, tranche first up the October to of then ADSs ADSs billion of the tranche on XXXX,
of During second our period trading were total satisfy the at used arrangements. the assets average program. our our $X.X of total the to share from $XXX.XX program a were for March XX, XXXX, for repurchased May plan approximately ADSs repurchase The capital. obligations of payment consideration number of share-based a X, settlement representing the an partially when ADSs date share The ADSs under under tranche to repurchased, X.X% net were billion price approximately the expired, X,XXX,XXX XXXX of repurchased
financial guidance following vaccine Before I assumptions and provide page, the considerations full in like on to the amongst year of specifically the revenues. XXXX some are which, would guidance, provide COVID-XX described our I our expected on key XXXX others,
purchase We to starting commercial expect advanced environment a transition agreement XXXX. from in market ordering an
variants or assumption guidance COVID-XX revenue asked to adapt newly of based addition, on In sublineages SARS-CoV-X. be is vaccine the that the to developers vaccine circulating will our
rephasing revenue with and/or the across traditional Currently, commercial under anticipated ongoing reflects is a Commission contract of COVID-XX years for volume committed existing vaccine the and contracts dose well existing through multiple European expected deliveries supply with of reduction. renegotiation or orders. a as the guidance potential deliveries Our sales
will primary for need the variant expect also lower significantly half are demand, of second the XXXX. anticipated. levels towards generation demand fewer We're seeing we and year a population-wide new vaccinations vaccine drive the boosters seasonal will increase revenue adapted While of
next I the by note, potential reflect XXXX to collaborations to the driven Company's for or additional outlook year. been would M&A or rates. constant transactions projections, they are include with base slide. you financial disclosed caused case to turn now like potential following from share the numbers and calculated based Let's the effects extent have the Please on currency current
Fosun, collaboration We believe and we that partners, for are well provider. positioned vaccine future the Pfizer our and as a COVID-XX leading
year, the mentioned €X XXXX assumptions. around For vaccine revenues previously financial billion we somewhere on estimate based of the base COVID-XX
COVID-XX to is as success. will Thanks for The our late-stage resources our into use our pipeline strong to oncology believe a four of as Broadening We to expanding performance, the be other programs to our disease from and basis the further vaccine our been in diversified of our aim drug of position across of continued financial company's financial diseases and never accelerate infectious product advancement We transformation BioNTech. our of our the the generated the we've to expand continuing clinical focus. pipeline accelerating our and capabilities commercialization and in and accelerate in existing well. our paramount regulatory responsible development, classes. of better platform approval invest pipeline the well sale clinical candidates our is areas as BioNTech
to our in forward. going intend invest As broadening the last week, pipeline shown already in of we course
€X.X continue in expenses. billion For spend range be of the estimated €XXX of SG&A financial the our for R&D range and Capital we for the plan business to in to we invest the to are expenses between €X.X fully powerhouse. making expected the XXXX year million to plan to billion million million million. expenditures immunotherapy in XXXX BioNTech €XXX to to existing €XXX as integrated €XXX year, be in financial are global,
in expand example, R&D area. support our digitalization and the IT invest facilities enhance state-of-the-art process especially planning to infrastructure R&D manufacturing and for a our to are, We further in to and
the effective XXXX. might further BioNTech the XX%. reminded of for year that during annual not the the invest activities in be expect calendar income or guidance the M&A estimated Group financial rate cash from around collaborations Company include tax at we Finally, that does the Please impact
to would center areas highlight key framework. now I the of like at our opportunity activities. capital are our take The the allocation to
foremost, R&D. and First
with Therefore, We various additional key make shareholders We people that further have how and value create to patients, to and translation into as for forward. our science novel can a technologies proven diseases. and remains This for believe improve the medicines and really our our people's science our the that world difference health cope intend our can we area accelerate we going investments the further whole. of long-term a to initiatives society worldwide.
M&A business and capabilities, digital and technologies acquisitions expertise we our and and extend development. synergistic supplement our Secondly, augment collaborations. To with to strive
XXXX. Also January announced XX,XXX personalized mRNA cancer For example, by a patients the in closing intelligence January the with a in to up we their commercialize to InstaDeep strategic entered OncoCX artificial global transaction leading field XXXX, into approvals. announced candidates. next-generation technology XXXX, that partner. we and and strategic The with immunotherapies of acquire exclusive and is an learning license in customary partnership UK long-time Ltd., provide agreement machine last we government to we worldwide collaboration company U.S.-based co-develop agreement On of Monday conditions and a and to anti-CTLA-X announced regulatory with week, monoclonal an antibody to subject
amount to again the $X.X the pursuant up year success. our in may shareholders repurchase XXXX. additional Consequently, we share during of ADSs billion ADSs of start in repurchase to we which would to participate program an like our Thirdly, we'll
truly other this setting, in years first, the with U.S., towards as to in countries starting an into to BioNTech. like opportunity a standard governments setting been year has more rate XXXX for We the move a are jurisdictions. expected more and be commercial XXXX is contractual and agreements commercial come. successful a where with moving year later a to flu in
given placed COVID-XX technology for tremendously the well based partners. with that offers has partnership for favorable be been to basis both mRNA believe that successful We and vaccines Pfizer the commercial on
ongoing and franchise and next benefit We contribution of from profit our relation and existing flow for expect COVID-XX BioNTech. given to revenues from years in vaccine our costs relevant the anticipate financially and the cash
with strategic Officer, would for an the Chief our on to update that, outlook to turn Strategy And I our XXXX Ryan like Richardson, remarks. call you. concluding Thank for over and
